Edinburgh Research Explorer

Mast Cells Express 11 beta-hydroxysteroid Dehydrogenase Type 1: A Role in Restraining Mast Cell Degranulation

Citation for published version:

Digital Object Identifier (DOI):
10.1371/journal.pone.0054640

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS One

Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 26. Nov. 2018
Mast Cells Express 11β-hydroxysteroid Dehydrogenase Type 1: A Role in Restraining Mast Cell Degranulation

Agnes E. Coutinho1,2, Jeremy K. Brown4, Fu Yang1,2, David G. Brownstein3, Mohini Gray2, Jonathan R. Seckl1, John S. Savill2, Karen E. Chapman1*

1 University/British Heart Foundation Centre for Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom, 2 Medical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom, 3 Mouse Pathology Core Laboratory, University of Edinburgh, Edinburgh, United Kingdom, 4 Medical Research Council Centre for Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom

Abstract

Mast cells are key initiators of allergic, anaphylactic and inflammatory reactions, producing mediators that affect vascular permeability, angiogenesis and fibrosis. Glucocorticoid pharmacotherapy reduces mast cell number, maturation and activation but effects at physiological levels are unknown. Within cells, glucocorticoid concentration is modulated by the 11β-hydroxysteroid dehydrogenases (11β-HSDs). Here we show expression and activity of 11β-HSD1, but not 11β-HSD2, in mouse mast cells with 11β-HSD activity only in the ketoreductase direction, regenerating active glucocorticoids (cortisol, corticosterone) from inert substrates (cortisone, 11-dehydrocorticosterone). Mast cells from 11β-HSD1-deficient mice show ultrastructural evidence of increased activation, including piecemeal degranulation and have a reduced threshold for IgG immune complex-induced mast cell degranulation. Consistent with reduced intracellular glucocorticoid action in mast cells, levels of carboxypeptidase A3 mRNA, a glucocorticoid-inducible mast cell-specific transcript, are lower in peritoneal cells from 11β-HSD1-deficient than control mice. These findings suggest that 11β-HSD1-generated glucocorticoids may tonically restrain mast cell degranulation, potentially influencing allergic, anaphylactic and inflammatory responses.

Introduction

Mast cells play a central (typically initial) role in inflammatory and allergic reactions. They guard against bacterial pathogens and participate in tissue repair by producing mediators that promote vascular permeability, angiogenesis and fibrosis. Mast cells accumulate in chronically inflamed tissues in humans and in mice, and have consistently been observed in high numbers in human rheumatoid arthritis (reviewed, [1]), in Crohn’s disease (reviewed, [2]) and in the bronchus of asthmatic patients [3,4]. Mast cells contain preformed tumour necrosis factor (TNF-α) in granules and can rapidly produce large amounts of both TNF-α and interleukin (IL)-1 [5] as well as other mediators, including histamine, eicosanoids (particularly prostaglandin D2) and vascular endothelial growth factor, which contribute to oedema, inflammation, hyperplasia and neovascularisation.

Glucocorticoids reduce mast cell number, maturation and activation [6,7,8,9], contributing to the potent anti-allergic and anti-inflammatory effects of these steroids. Blood glucocorticoid levels depend upon activity of the hypothalamic-pituitary-adrenal axis. However, intracellular glucocorticoid concentrations can differ greatly from blood levels due to the action of 11β-hydroxysteroid dehydrogenase (11β-HSD), an enzyme that interconverts active glucocorticoids (cortisol in humans, corticosterone in rodents) and intrinsically inert 11-keto metabolites (cortisone, 11-dehydrocorticosterone). Two isozymes exist; 11β-HSD1 and 11β-HSD2. Whereas 11β-HSD2 inactivates glucocorticoids and is largely restricted to mineralocorticoid target tissues in the adult, 11β-HSD1 catalyses the opposite reaction in vivo, predominantly reactivating glucocorticoids by converting inert 11-keto-glucocorticoids into active forms and shows a more widespread distribution [10]. Mice homozygous for a targeted disruption of the Hsd11b1 gene that encodes 11β-HSD1 (Hsd11b1−/− mice) have normal blood glucocorticoid levels on the C57BL/6J strain background [11] yet have a phenotype consistent with intracellular glucocorticoid deficiency (reviewed, [12]). Thus, they exhibit more severe acute inflammation in models of myocardial infarction, arthritis, sterile peritonitis and carrageenan-induced pleurisy [13,14], suggesting 11β-HSD1 normally exerts a restraining influence upon the early inflammatory response. In vivo, 11β-HSD1 expression is rapidly and markedly increased at sites of inflammation, including in peritoneal immune cells during sterile peritonitis [15], in colitis [16,17] and in the arthritic joint [18]. 11β-HSD1 is expressed in macrophages [15,19] where it performs an anti-inflammatory
function, accelerating acquisition of macrophage phagocytic competence [15]. Expression has also been shown in dendritic cells [20], neutrophils [21] and lymphocytes [22], though its role in these cells remains uncharacterised. Here, we describe expression and activity of 11β-HSD1 in mast cells, classical glucocorticoid-targets in allergic and anaphylactic reactions, and demonstrate a restraining influence of 11β-HSD1 on mast cell degranulation.

Materials and Methods

Ethics Statement

All animal experimentation was conducted in strict accord with accepted standards of humane animal care under the auspices of the Animal (Scientific Procedures) Act UK 1986 following prior approval by the local University of Edinburgh ethical committee.

Animals

Mice homozygous for a targeted disruption of the 

Hsd11b1 gene on a C57BL/6 background (>8 backcrosses) have been described [15]. Control age-matched C57BL/6 (Hsd11b1/+×) mice were bred in-house. Mice were housed in groups of 2–5 per cage under controlled conditions (12 h-light/dark cycle, 21°C) with ad libitum access to water and standard rodent chow.

Generation of Anti-glucose 6-phosphate Isomerase IgG Immune Complexes

Arthritogenic K/BxN serum containing anti-glucose 6-phosphate isomerase (GPI) IgG immune complexes was generated in house from arthritic K/BxN mice (expressing both the KRN T gene, Paisley, UK) supplemented with 10% FCS, 500 U/ml penicillin, 500 U/ml streptomycin and 10% conditioned medium from murine fibrosarcoma cell (L929) cultures.

Bone Marrow-derived (BMD) Mast Cell and Macrophage Cultures

BMD-mast cells and BMD-macrophages were cultured as previously described [15,23] from 10 week old male C57BL/6 mice. Briefly, BMD-mast cells were obtained following 21d incubation in DMEM medium supplemented with recombinant mouse IL-3 (1 ng/ml) and SCF (50 ng/ml) (PeproTech EC Ltd, London, UK). Mast cell purity was confirmed by immunofluorescent staining with tryptase (mMCP-6) antibody and this protocol routinely gives >98% pure mast cells [24]. BMD-macrophages were obtained following 7d incubation in DMEM/F12 (Invitrogen, Paisley, UK) supplemented with 10% FCS, 500 U/ml penicillin, 500 U/ml streptomycin and 10% conditioned medium from murine fibrosarcoma cell (L929) cultures.

Assay of 11β-HSD1 Activity

11β-HSD1 activity (dehydrogenase and reductase) was measured as previously described [15]. Briefly, 200 nM corticosterone or 11-dehydrocorticosterone, containing trace amounts of [3H]-corticosterone (specific activity ~80 Ci/mmol; Amersham Pharmacia Biotech, Buckingham, UK) or [3H]-11-dehydrocorticosterone (made as previously described; [15]), was added to cell culture medium. At various times steroids were extracted in triplicate and analysed either by thin layer chromatography or by high performance liquid chromatography as previously described [15].

RNA Extraction and Analysis

Total RNA was extracted from cells as previously described [15]. For RT-PCR, 1 μg RNA was reverse transcribed and subjected to PCR as described [15]. 11β-HSD2 primers: forward, 5'-CTGAAGCTGCTGACAGTTGGAT-3' and reverse, 5'-GAGCCAGCCAGCCTGTAGTATG-3'. 11β-HSD1 PCR reactions all used a common reverse primer, 868P 5'-AGGATC-CARAGAAACATTGCTGCA-3', complementary to exon 6, and one of the following forward primers: 869P 5'-AAAGCTTGCACWGCGGCCCAGCAA-3', in exon 3, common to all 11β-HSD1 transcripts; ex2, 5'-GTCCGCTTTTTGATGTCGAC-3', in exon 2, common to P1 and P2 transcripts; P1, 5'-GGAGCCCCGTATATCTGAA-3', specific for transcripts arising from P1; P2, 5'-GGAGGTTTGTA-GAAAGCTCTG-3', specific to transcripts arising from P2; P3, 5'-GTAATGGAACCGAAGCAAGG-3', specific for transcripts arising from P3 (in the intron between exons 2 and 3). Real-time PCR was carried out on a LightCycler 480, according to the manufacturer’s instructions. Mastermix and primer-probe sets for 18S RNA (4331182), TATA-Binding Protein (TBP) (Mm00446973_m1), carboxypeptidase A3 (Mm00483940) and annexin 1 (Mm00440225_m1) cDNAs were purchased from Applied Biosystems (Warrington, UK). Neither internal standard differed between genotypes and accordingly TBP was used as the internal standard.

Analysis of Peritoneal Mast Cells

For analysis of peritoneal mast cells, 8–12 week old male and female mice were used. Following peritoneal lavage, enriched peritoneal mast cells were prepared from freshly isolated peritoneal cells, positively selected for CD117+ mast cells using magnetic beads (Miltenyi Biotec, Surrey UK) according to the manufacturer’s instructions. Generally, around 50% pure mast cell populations were achieved based on histochemical staining of cytocentrifuge preparations or flow cytometry analysis. Mast cell degranulation was determined by measuring the release of β-hexosaminidase as described [25]. Briefly, peritoneal cells were incubated in triplicate for 15 min at 37°C in Tyrode’s Buffer and were untreated or treated with 10 μM ionomycin or diluted K/ BxN serum. Following incubation, cells were collected by centrifugation. Aliquots (in triplicate) of the supernatant were transferred to a 96-well plate. The remaining supernatant was carefully removed and cell pellets solubilized in Tyrode’s buffer with the addition of 0.5% Triton X-100. β-hexosaminidase (1 p-nitrophenyl-β-D-glucosamino) was added to each well and incubated for 40 min at 37°C. Reactions were stopped by the addition of glycine and absorbance was measured at 405 nm. Total mast cell β-hexosaminidase was measured in untreated cells solubilized by the addition of Triton X-100. For each sample, degranulation was calculated as A405 supernatant/A405 supernatant+A405 pellet. The mean of the untreated samples in each group was arbitrarily set to 100, and all other values expressed relative to this. Net degranulation was calculated as the difference between treated and untreated samples (and is thus % degranulation above levels in untreated cells). In preliminary experiments, no differences in mast cell number or level of degranulation were observed between the sexes of either genotype, therefore total peritoneal cells from both sexes were used.

Flow Cytometry

Anti-mouse CD117 (e-Kit)-phycoerythrin (PE) or -allophyco- cyanin (APC), anti-mouse FcγR-PerCP Cy5.5, FcεR-PE and IgG controls (eBiosciences, Middlesex, UK) were added to peritoneal cells at concentrations recommended by the supplier and incubated on ice for 30 min in the dark. 11β-HSD1 sheep-derived antibody, generated in-house [26], was used in combination with Donkey
Figure 1. Mast cells express 11β-HSD1. (A) 11β-HSD1 reductase (conversion of 11-dehydrocorticosterone to corticosterone; Solid lines/black squares) and dehydrogenase (conversion of corticosterone to 11-dehydrocorticosterone; dashed lines/open squares) activities in BMD-MC (>98% pure, assessed by tryptase staining as previously described [24]) are expressed as % conversion of 200 nM substrate by 2×10⁶ cells, over time (h). Values are mean ± SEM of 3 independent assays carried out on pooled BMD-MC. (B) BMD-MC express 11β-HSD1 mRNA (upper panel; 469 bp RT-PCR product with primers 868P and 869P) but not 11β-HSD2 mRNA (lower panel; 400 bp RT-PCR product). Lanes 5 and 6 show RT-PCR products from 2 independent Hsd11b1+/+ BMD-MC RNA samples. Positive controls (+) comprised liver mRNA (lane 4, upper panel) or kidney mRNA (lane 4, lower panel). Negative controls contained BMD-MC RNA but no reverse transcriptase (−, lane 3) or water (lane 2). Lane 1 contains a 100 bp ladder.
(Promega, Southampton, UK). (C) Hsd11b1+/− BMD-MC lack 11β-HSD1 activity. 11β-HSD1 reductase activity was measured in Hsd11b1+/+ (+/+ and Hsd11b1−/− (−/−) BMD-MC. Data are expressed as % conversion of 200 nM 11-dehydrocorticosterone to corticosterone by 2×10^6 cells in a 10 h assay. Values are means of triplicate assays performed on pooled BMD-MC. ND, not detected. (D) Mast cells transcribe Hsd11b1 from the P1 promoter, whereas macrophages use the P2 promoter. Upper panel: RT-PCR products from 3 independent BMD-MC RNA samples showing the 627 bp RT-PCR product from P1 transcripts of 11β-HSD1 (lanes 4–6), but not P2 (predicted product of 647 bp, lanes 7–9) or P3 (predicted product of 542 bp, lanes 10–12). Kidney RNA confirmed transcription from P3 (not shown). Total 11β-HSD1 mRNA was detected using ex2 and 868P primers common to all transcripts (lanes 13–15, 587 bp product). Lower panel: RT-PCR products from BMD macrophage RNA showing the 647 bp RT-PCR P2 product (lane 3), but not the P1 (lane 2) or P3 products (lane 4). Total 11β-HSD1 mRNA (T) was detected using 868P and 869P primers, common to all transcripts (lanes 5, 6, 469 bp product). Lane 1 contains a 1 kb ladder (Invitrogen, Paisley, UK). Lanes marked (0) contain water only and lanes marked (v) isotype control for CD117 and (vi) CD117 antibody only. Panel (vii) shows cells double stained with 11β-HSD1 and CD117 antibodies. doi:10.1371/journal.pone.0054640.g002

Figure 2. More mast cells in the peritoneum of Hsd11b1−/− mice. (A) Representative dot plots of freshly isolated peritoneal cells (5×10^6) from Hsd11b1+/+ (left) and Hsd11b1−/− (middle) mice stained for CD117 (a mast cell marker) or isotype control (right) and subject to flow cytometry. (B) Peritoneal cells from Hsd11b1−/− mice (−/−, white bars) have more CD117+ cells than Hsd11b1+/+ (+, black bars), expressed as percentage of total cells (total cell number; Hsd11b1+/+, 3.8±0.5×10^6 vs Hsd11b1−/−, 3.7±0.5×10^6, p>0.05). (C) CD117+ cells from Hsd11b1−/− mice have higher mean fluorescence intensity (MFI) compared to Hsd11b1+/+ mice (black bars). Data are mean ± SEM, n=8, *p<0.05, **p<0.01. doi:10.1371/journal.pone.0054640.g002
Results

11β-HSD1 is Expressed in Mast Cells

With 11-dehydrocorticosterone as substrate, BMD-mast cells show 11β-keto-reductase activity (Figure 1A; 16.9±1.1 pmol corticosterone/h/10⁶ cells). In contrast, BMD-mast cells show negligible 11β-dehydrogenase activity with corticosterone as substrate (Figure 1A) showing the absence of 11β-HSD2 and indicating 11β-HSD1 is a predominant 11β-reductase in mast cells. Consistent with this, 11β-HSD1 mRNA is present and 11β-HSD2 mRNA absent in mast cells (Figure 1B). BMD-mast cells from 11β-HSD1-deficient mice lack 11β-HSD1 activity (Figure 1C), confirming the activity is due to 11β-HSD1. 11β-HSD1 mRNA is transcribed from 3 distinct promoters [27,28]. Transcription of the Hsd11b1 gene in BMD-mast cells initiates at the upstream P1 promoter, with little or no transcription from the downstream P2 and P3 promoters (Figure 1D). Importantly, this contrasts with BMD-macrophages which exploit the P2 promoter (Figure 1D), suggesting that these P1-initiated transcripts are in mast cells and not in contaminating macrophages. CD117 or c-Kit, is a marker for mature mast cells. Flow cytometric staining of lavaged peritoneal cells (of which ~3% are mast cells; see Figure S1 for definition of the CD117 population) with 11β-HSD1 antibody demonstrates immunoreactive protein in CD117+ cells (Figure 1E), confirming 11β-HSD1 expression in mast cells in vivo as well as in vitro.

11β-HSD1-deficiency Alters Peritoneal Mast Cell Number and Phenotype

Mast cell number and phenotype are both influenced by glucocorticoids [6,7,8,9]. To address whether either are affected by 11β-HSD1-deficiency, peritoneal mast cells from naive Hsd11b1−/− mice were subject to flow cytometry. More CD117+ cells are present in the peritoneum of naive Hsd11b1−/− mice than controls (Figure 2A, B) and CD117+ cells from Hsd11b1−/− mice have higher mean fluorescence intensity (Figure 2C) suggesting increased surface expression of CD117 on peritoneal mast cells of Hsd11b1−/− mice. However, the proportion of CD117+ cells also positive for FcεR and FcγR mast cell markers is the same in both genotypes (96.8±0.4% of Hsd11b1−/− and 96.9±0.9% of Hsd11b1+/− CD117+ cells express both FcεR and FcγR markers) with no difference in mean fluorescence intensity of these receptors between genotypes (FcεR; mean fluorescence intensity; Hsd11b1+/−: 31.2±0.5 vs Hsd11b1−/−, 28.3±2.0 and FcγR-PerCP Cy5.5 mean fluorescence intensity; Hsd11b1+/−, 51.5±2.0 vs Hsd11b1−/−, 53.9±0.5).

To determine whether mast cell contents are affected by 11β-HSD1 deficiency, key glucocorticoid-regulated transcripts were examined. Levels of mRNA encoding carboxypeptidase A3,

![Figure 3. Decreased levels of glucocorticoid-sensitive transcripts in peritoneal cells from Hsd11b1−/− mice.](image)

![Figure 4. Ultrastructural analysis suggests piecemeal degranulation in Hsd11b1−/− mast cells.](image)
regulated mast cells.

Mice were aged 7-8 weeks old and both genotypes were weaned onto a standard chow diet for four weeks before experiments. Enriched peritoneal mast cells were prepared from mice (5 per mouse) by layering 4% BSA in PBS onto the peritoneal cavity of mice. The interface between PBS and BSA was aspirated, and the cell suspension was filtered through a 40-μm cell strainer to remove adherent cells. After washing, enriched peritoneal mast cells were obtained by centrifugation and resuspended in complete medium (CM; 10% FBS, 0.1% sodium azide, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 μg/ml gentamycin, 100 μM non-essential amino acids, 10 mM HEPES, 2 mM glutamine). Cell viability was ≥95% as determined by trypan blue staining. Asynchronously divided mast cells were maintained at 37°C in a humidified 5% CO₂ incubator. Peritoneal mast cell count was determined using a hemocytometer. Peritoneal mast cell cell viability was ≥95% as determined by trypan blue staining.

Results

11β-HSD1 Deficiency Reduces the Activation Threshold of Peritoneal Mast Cells

To determine whether 11β-HSD1 deficiency functionally alters mast cell sensitization, we measured mast cell degranulation by assaying β-hexosaminidase release. Maximal degranulation induced by 10 μM ionomycin was similar in peritoneal mast cells from Hsd11b1−/− and control mice (Figure 5A). A similar maximal level of degranulation was observed following 15 min incubation with a 1:2 dilution of K/BxN serum (containing anti-glucose 6-phosphate isomerase IgG immune complexes, a potent trigger of mast cell degranulation) into culture medium (Figure 5B). However, 15 min incubation with a lower concentration of K/BxN serum (diluted 1:8 in medium) induced significantly more degranulation of peritoneal mast cells from Hsd11b1−/− than control mice (Figure 5B). Furthermore, when an enriched population of peritoneal CD117− cells (~50% mast cells) was incubated for 21 h with K/BxN serum (diluted 1:8 in medium), microscopic examination revealed extensive degranulation of 11β-HSD1-deficient mast cells, whereas controls showed little or no degranulation (Figure 5C). 11β-HSD1-deficiency therefore lowers the threshold for degranulation of resident mast cells following IgG immune complex activation.

Discussion

Pharmacological levels of glucocorticoids have potent effects on mast cells, but effects of endogenous glucocorticoids at physiological levels are unknown. Mast cells from Hsd11b1−/− mice have a phenotype consistent with relative glucocorticoid deficiency, including reduced expression of glucocorticoid-sensitive mast cell-specific carboxypeptidase A3, suggesting 11β-HSD1-mediated glucocorticoid amplification tonically suppresses mast cell responses.

11β-HSD1 is expressed in both BMD- and in peritoneal mast cells. At around 10–20 pmol/h/10^6 cells, the level of keto-reductase activity in BMD-mast cells is considerably higher than that reported for T lymphocytes (<0.1 pmol/h/10^6 cells; [22]) and comparable with levels in immature BMD-dendritic cells (7 pmol/h/10^6 cells; [20]) and BMD-macrophages (12 pmol/h/10^6 cells). Thus, the measured activity is likely to be due to mast cells and not to contamination with macrophages or another cell type expressing 11β-HSD1, present at <2% of the population. This is supported by the use of the P1 promoter in mast cells, which contrasts with most other tissues and cell types, including macrophages, that use the P2 promoter and suggests a distinct regulation in mast cells.

Whilst the maximum response to degranulating stimuli was similar in mast cells from Hsd11b1−/− and control mice (suggesting Hsd11b1−/− mice have normal levels of β-hexosaminidase in stored granules), 11β-HSD1-deficient cells were sensitive to a low dose of K/BxN serum that was ineffective in control cells, suggesting that it is the threshold for activation that is reduced, rather than the total number of stored granules, which was unchanged in Hsd11b1−/− mice. Ultrastructural analysis of peritoneal mast cells supported this “trigger-happy” phenotype of Hsd11b1−/− mast cells and indicated piecemeal degranulation, a slower form of non-anaphylactic degranulation, that has been associated with persistent inflammation [32].

11β-HSD1 in Mast Cells

Figure 5. Hsd11b1−/− peritoneal mast cells are hyper-responsive to degranulation induced by K/BxN serum. Release of β-hexosaminidase from peritoneal cells (2×10^5) was measured following 15 min incubation with either (A) 10 μM ionomycin or (B) K/BxN serum (diluted 1:8 or 1:2 in Tyrode’s buffer). Black bars, Hsd11b1+/+; white bars, Hsd11b1−/−. Data are net degranulation in treated cells above levels measured in untreated cells (cells only are set to zero; see methods for details), and are mean ± SEM; n=12–13, *p<0.05. (C) Representative micrographs (captured at 40× magnification) of enriched peritoneal CD117− cells from Hsd11b1−/− (+/+, left panels) or Hsd11b1−/− mice (−/+ −, right panels) following 21 h incubation with buffer (top panels) or K/BxN serum (1:8 dilution) (lower panels). Arrowheads indicate degranulated mast cells.

doi:10.1371/journal.pone.0054640.g005

Generally considered a mast cell-specific product [29,30] that is glucocorticoid-inducible [8], lower in peritoneal cells from Hsd11b1−/− mice, compared to controls despite increased peritoneal mast cell number, consistent with reduced intracellular glucocorticoid action in 11β-HSD1-deficient mast cells (Figure 3A). Moreover, although not mast cell-specific, levels of annexin I mRNA (formerly called lipocortin), a classic glucocorticoid-inducible gene [31], are also reduced in peritoneal cells from Hsd11b1−/− mice (Figure 3B).

To investigate whether the characteristic granule morphology of mast cells is affected by 11β-HSD1-deficiency, transmission electron microscopy was carried out on an enriched population of peritoneal mast cells (~50% mast cells). Total granule number per cell did not differ between genotypes Hsd11b1+/+55.6±14.7 (n = 41) vs Hsd11b1−/−61.6±19.4 (n = 49). However, whereas mast cells from control mice predominantly contain homogeneously electron dense granules (Figure 4A), those from Hsd11b1−/− mice are more heterogeneous and contain a greater proportion of lighter granules (Figure 4A, B) as well as enlarged partially filled and empty vesicles, characteristic of piecemeal degranulation [32], a slower form of mast cell degranulation than anaphylactic degranulation.
FcγR, key for IgG-mediated signalling, is normal on 11β-HSD1-deficient mast cells, though it is possible that the threshold for FcγR activation and signalling is reduced. Mast cell number was increased by ~34% in the peritoneum of Hsd11b1−/− mice. Mast cell number is reduced by pharmacological glucocorticoid treatment in vivo, though whether normal physiological glucocorticoid concentrations have a similar effect in vivo has not been reported. However, given that Hsd11b1−/− mice have normal plasma corticosterone levels on this genetic background [39] and we have previously shown normal responses of Hsd11b1−/− immune cells to exogenous corticosterone [15], the increase in the number of mast cells in the peritoneum of Hsd11b1−/− mice suggests that 11β-HSD1-mediated regeneration of endogenous intracellular glucocorticoids limits proliferation of at least some mast cell populations. In this respect, it is interesting that activation products of mast cells are chemotactic for their progenitors [34,35], suggesting that the basal activation observed in Hsd11b1−/− mast cells may underlie the increase in peritoneal mast cell number.

Immune activation is a potent stimulus to the hypothalamic-pituitary-adrenal (HPA) axis and removal of endogenous glucocorticoids or blockade of their actions exacerbates immune and inflammatory disease in humans and in animal models (reviewed, [36]). Our data suggest that by providing a “brake” to spontaneous mast cell degranulation, 11β-HSD1-mediated amplification of endogenous glucocorticoid action within mast cells may influence allergic and anaphylactic reactions, in which mast cells are central, and for which glucocorticoid pharmacotherapy remains a highly effective treatment. Experimental testing of this hypothesis in appropriate in vivo models of anaphylaxis and allergy will be important in the future. These will be important considerations in the clinical introduction of selective 11β-HSD1 inhibitors for treatment of metabolic disease, a side-effect of which could be mast cell hyper-responsiveness.

Acknowledgments

We thank Steve Mitchell for carrying out the electron microscopy, Pamela Knight for providing additional BMD-mast cell cDNA, Tiina Kipari for advice and assistance with flow cytometry analysis, staff of the BRR and Spike Clay for expert animal assistance and colleagues, especially Alan Pemberton and Hugh Miller, for helpful discussions.

Supporting Information

Figure S1 Flow cytometric assessment of mast cells using an enriched population of CD117+ peritoneal cells. Freshly obtained total peritoneal cells (3.8×106 cells pooled from 6 mice) were labeled with CD117 magnetic beads and purified using a MACS magnet. (A) Using flow cytometry separate populations; total cells (i−ii), CD117+ (iii−iv) and CD117− (v−vi) cells were assessed for mast cells using side scatter (SSC), forward scatter (FSC) and staining with CD117 antibody. Panels (i, iii, v) illustrate the gate for high SSC/CD117+ cells, while panels (ii, iv, vi) illustrate where the high SSC/CD117+ cells (black) are positioned against all cells in the sample (grey). This gate was then used to select for mast cells in all experiments. (B) Mast cells were confirmed by staining the CD117+ enriched-high SSC/CD117+ population of cells (A; iii right gate) with Fc Gamma receptor (Fc Gamma R) and Fc Epsilon receptor (Fc Epsilon R) (markers of mast cells) antibodies (iii). Panel (i) shows single stain control for CD117 only, in the high SSC/CD117+ population of cells, negative for Fc Gamma R and Fc Epsilon R staining. (TIF)

Author Contributions

Conceived and designed the experiments: AEC MG JRS JSS KEC. Performed the experiments: AEC JKB FY. Analyzed the data: AEC DGG KEC. Contributed reagents/materials/analysis tools: AEC JKB FY MG. Wrote the paper: AEC KEC.

References


